StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Convertible Debentures $200,000 CAD

<< Previous

Bullboard Posts

Next >>

Comment by Liked2Thinkon Aug 23, 2022 2:48pm

148 Views

Post# 34914978

RE:Convertible Debentures $200,000 CAD

Its nice to think they dont need anymore money but that doesnt fly with what Tripp said in the CC about throwing more money at marketing to do this.

So how do you know the $200k is because they dont need anymore rather than it only being $200K because thats all they could get?

There is no proof that backs up one way or the other.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing